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ABSTRACT
The directed differentiation of human pluripotent stem cells, such as embryonic stem cells
(hESCs) and induced pluripotent stem cells (hiPSCs), into pancreatic endocrine lineages
has been vigorously examined by reproducing the in vivo developmental processes of
the pancreas. Recent advances in this research field have enabled the generation from
hESCs/iPSCs of functionally mature b-like cells in vitro that show glucose-responsive insulin
secretion ability. The therapeutic potentials of hESC/iPSC-derived pancreatic cells have
been evaluated using diabetic animal models, and transplantation methods including
immunoprotective devices that prevent immune responses from hosts to the implanted
pancreatic cells have been investigated towards the development of regenerative thera-
pies against diabetes. These efforts led to the start of a clinical trial that involves the
implantation of hESC-derived pancreatic progenitors into type 1 diabetes patients. In addi-
tion, patient-derived iPSCs have been generated from diabetes-related disorders towards
the creation of novel in vitro disease models and drug discovery, although few reports so
far have analyzed the disease mechanisms. Considering recent advances in differentiation
methods that generate pancreatic endocrine lineages, we will see the development of
novel cell therapies and therapeutic drugs against diabetes based on iPSC technology-
based research in the next decade.
INTRODUCTION
Type 1 diabetes is an autoimmune disease characterized by
b-cell destruction in the pancreas, insulin deﬁciency and persis-
tent high blood glucose levels. Although the supplementation of
exogenous insulin is a life-saving treatment, it is still difﬁcult to
obtain physiological control of blood glucose levels. The trans-
plantation of pancreatic b-cells as islet tissues or the entire pan-
creas is an alternative curative treatment for type 1 diabetes1–3.
However, transplantation therapies are hampered by a serious
donor shortage and the potential risk of tissue rejection. One
possible solution to the donor shortage is the generation of
b-cells or islet tissues from human pluripotent stem cells, such
as embryonic stem cells (hESCs)4 and induced pluripotent stem
cells (hiPSCs)5,6. The directed differentiation of pancreatic lin-
eage cells from hESCs/iPSCs has been vigorously studied
towards regenerative therapy for type 1 diabetes, as well as
basic pancreatic research7–22.
Substantial progress in this research ﬁeld has been made in
recent years. In the USA, phase 1/2 clinical trials for type 1
diabetes patients have already been started with the use of
hESC-derived pancreatic progenitors. In contrast, at the time of
writing the present review, there have been no clinical trials
carried out using the transplantation of hiPSC-derived pancre-
atic cells. Because of the potential advantages of hiPSCs over
hESCs, however, such as the practicability of autologous cell
transplantation and fewer ethical problems, research in hiPSC-
based therapy is expected to lead to such therapy in the future.
In the present review, we summarize recent advances in
research on pancreatic regeneration and disease modeling using
pluripotent stem cells, and also outline future perspectives of
the clinical application for diabetes.
NEW CELL SOURCES
Pancreatic b-cells secrete insulin, a hormone that plays a cru-
cial role in the regulation of blood glucose levels. In type 1
diabetes, pancreatic b-cells are destroyed, which results in
absolute deﬁciency of insulin. If patients’ blood glucose levels
are not properly controlled, a variety of serious complications
take place. Although the risk of complications in type 1 dia-
betes patients has declined with recent advances in medical
care, type 1 diabetes patients must always take care to controlReceived 3 March 2017; revised 1 June 2017; accepted 4 June 2017
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their blood glucose levels by multiple daily insulin injections,
which causes a great burden to the patients, to prevent
complications.
In type 1 diabetes, the supplementation of pancreatic b-cells
is considered one of the most potentially effective treatments
for diabetes. One supplementation approach is the transplanta-
tion of islets obtained from brain dead or cardiac arrest donors
through the portal vein. Although islet transplantation requires
a sufﬁcient number of islets from multiple donors, its safety
and efﬁcacy for the treatment of type 1 diabetes have been
shown, enabling patients to withdraw from insulin injection
therapy1–3. Islet transplantation is becoming approved as stan-
dard treatment around the world. This therapy has beneﬁted
from recent advances in isolation methods that stably obtain
islet tissues of sufﬁcient quality at the clinical level. However,
various problems, such as a serious shortage of donors and
side-effects of immunosuppressive agents, still remain to be
solved, preventing islet transplantation from becoming a univer-
sal treatment for diabetes.
In order to solve the problem of donor islet shortage, a new cell
source of human pancreatic b-cells is required. Pluripotent stem
cells, such as ESCs or iPSCs, which have the capability to indeﬁ-
nitely self-renew and differentiate into any cell type of the body,
are appealing candidates. Pancreatic b-cells generated from these
stem cells are expected as a new cell source for transplantation
therapy against diabetes. Since the report by Assady et al.23,
which for the ﬁrst time generated insulin-producing cells from
hESCs by spontaneous differentiation using embryoid body for-
mation, an efﬁcient generation of pancreatic b-like cells has been
vigorously studied by various approaches7–22. Such efforts have
made the clinical application of transplantation therapy using
pancreatic cells derived from pluripotent stem cells closer to
realization.
DIRECTED DIFFERENTIATION INTO PANCREATIC
b-CELLS
In order to induce the differentiation of hESCs/iPSCs into pan-
creatic lineage cells, a strategy has been adopted to mimic and
reproduce the normal developmental stages of the pancreas
in vitro by using the expression of key transcription factors
involved in pancreas development as an index. As shown in
Figure 1, a fertilized egg differentiates through multiple develop-
mental stages, such as deﬁnitive endoderm, primitive gut tube,
posterior foregut, pancreatic endoderm and endocrine precur-
sors, into insulin-expressing b-cells. In the case of hESC/iPSC
differentiation, similar developmental stages are induced using a
combination of growth factors or chemical compounds includ-
ing Nodal-activin, Wnt, retinoic acid, hedgehog, ﬁbroblast
growth factor, epidermal growth factor, bone morphogenetic
protein and Notch to activate or inhibit key signal pathways7–22.
Until recently, most investigators have generated pancreatic
b-like cells that produce and secrete insulin in response to
stimuli, such as potassium chloride7,17. However, these cells do
not secrete suitable amounts of insulin in response to changes
in blood glucose levels, making them inferior to adult b-cells.
In addition, the generated pancreatic b-like cells co-express
other hormones, such as glucagon and somatostatin. Gene
expression analysis has further shown that b-like cells induced
from hESCs/iPSCs do not accurately represent features of
mature adult b-cells and more closely resemble embryonic b-
cells24. In contrast, several groups including ours have reported
the generation of hESC/iPSC-derived embryonic pancreatic
endoderm cells that have the capacity to differentiate into all
pancreatic lineages including endocrine cells. These cells can
differentiate and mature in vivo into adult b-cells with the
capacity of glucose-stimulated insulin secretion 3–4 months




















Figure 1 | Schematic diagram of the differentiation strategy to produce pancreatic endocrine lineages from such as human embryonic stem cells
and induced pluripotent stem cells (hESCs/iPSCs) by mimicking in vivo development. The developmental stages and their corresponding marker
genes are shown.
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Our group also showed that high-cell density cultures, such as
adherent cultures at higher-cell density and cell aggregation cul-
tures, favored differentiation into pancreatic endoderm cells at
the pancreatic bud stage22. These ﬁndings suggest that hESC/
iPSC-derived pancreatic endoderm cells retain the potential to
differentiate into pancreatic endocrine cells that are functionally
comparable with adult b-cells.
More recently, two breakthrough papers have succeeded in
the generation of functionally mature b-like cells from hESCs/
iPSCs, although details on the maturation mechanism remain
to be elucidated. Rezania et al.20 optimized their differentiation
protocol by adding factors, such as vitamin C, protein kinase C
pathway activators, transforming growth factor-b receptor inhi-
bitors and thyroid hormones, to generate insulin-producing
cells at an induction rate of approximately 50%. Furthermore,
they identiﬁed R428, a selective small-molecule inhibitor of tyr-
osine kinase receptor AXL, as a crucial factor for the matura-
tion of b-cells. When the aforementioned insulin-producing
cells were treated with the factors and R428, the expression
level of MAFA messenger ribonucleic acid became higher than
that of human pancreatic islets, and the cells acquired a respon-
siveness to changes in glucose levels, although less potently than
that of adult human islets. After implantation into diabetes
mouse models, the engrafted cells improved the blood glucose
levels of host mice after 16 days, suggesting that insulin-produ-
cing cells suitable for cell therapy against diabetes could be
produced from hESCs in vitro.
Pagliuca et al.19 optimized their differentiation method for
pancreatic b-cells by examining more than 150 combination
treatments of >70 kinds of compounds. The group established
a 5-week long differentiation method of hESCs/iPSCs to b-cells
at an induction efﬁciency of >30%. The induced cells showed
insulin secretion and intracellular Ca2+ handling in response to
sequential changes in glucose concentrations. Furthermore, the
cells were similar to human islets in terms of stimulation index,
which is a ratio of insulin secretion levels between low- and
high-glucose conditions, amounts of insulin secretion, and
intracellular insulin content, suggesting they very closely resem-
bled adult b-cells. When the induced cells were implanted into
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Figure 2 | Pancreatic endoderm cells differentiated from human embryonic stem cells (hESCs) mature into b-cells in vivo. (a)
Section immunostaining images of hESC-derived pancreatic endoderm cells for PDX1 (green) and NKX6.1 (red), (b) human pancreatic tissues
generated 30 days after implantation of hESC-derived pancreatic endoderm into immunodeficient mice for PDX1 (green), INSULIN (red) and
GLUCAGON (blue), and (c) human islet-like structures generated 210 days after implantation. (d) Plasma human C-peptide levels in host
immunodeficient mice. Scale bars, 100 μm. Adapted from Toyoda et al.22 with permission (licensed under Creative Commons Attribution).
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cells started to secrete insulin in response to changes in blood
glucose levels as early as 2 weeks after implantation. After the
implantation into diabetes mouse models, the cells improved
blood glucose levels of the host mice for >18 weeks. Compared
with previously reported implantations of hESC/iPSC-derived
pancreatic endoderm cells, in which it took 3–4 months after
implantation for the cells to mature, recent advances in the
generation of b-cells in vitro substantially shorten the waiting
time to acquire therapeutic effects after implantation.
After these two reports, other groups have reported success
in the production of pancreatic b-like cells with the ability of
glucose-responsive insulin secretion by strictly regulating the
timing of the cell fate decision from pancreatic endoderm to
endocrine cells25–27. Although several issues, such as the stabil-
ity and cost of the differentiation, still remain to be improved
before clinical application, recent advances in the generation of
functionally matured b-like cells from hESCs/iPSCs in vitro are
expected to overcome the major obstacles for regenerative
medicine against diabetes.
Unbiased screenings have been used to identify small mole-
cules that induce the differentiation of hESC/iPSCs. Small mole-
cules with unique biological activities enable new biological
studies, and might further lead to the development of new
treatments by signiﬁcantly lowering the cost28. Two reports
have identiﬁed chemical compounds that act as inducers of
pancreatic lineage cells, indolactam V for PDX1+ pancreatic
progenitor cells12 and vesicular monoamine transporter 2 inhi-
bitors for INSULIN+ cells29.
GENERATION OF WHOLE PANCREAS BY BLASTOCYST
COMPLEMENTATION
Blastocyst complementation is an experimental strategy to gen-
erate whole organs in chimeric animals30. With this strategy,
ESCs/iPSCs are injected into blastocysts of animals in which
essential genes for the development of certain organs are
knocked out. Dr Hiromitsu Nakauchi and his research team are
leaders in this ﬁeld. They carried out blastocyst complementa-
tion by injecting wild-type mouse ESCs/iPSCs into Pdx1-/-
pancreatogenesis-disabled mice to generate a whole pancreas31.
Pancreatic islets removed from the generated whole pancreas
showed therapeutic effects when implanted into diabetes mouse
models. The group also showed that whole rat pancreas can be
generated by blastocyst complementation using the injection of
rat iPSCs into Pdx1-/- mice, although the generated pancreas
was mouse size31. Very recently, the same group carried out the
reverse experiment, generating rat-sized pancreas consisting of
mouse ESCs/iPSCs by injecting them into Pdx1-/- rat blasto-
cysts. Mouse islets from the generated pancreas maintained
blood glucose levels of diabetic mice induced by streptozotocin
over 370 days after implantation without immunosuppression32.
These ﬁndings show that whole human pancreas could be inter-
speciﬁcally generated from hESCs/iPSCs by blastocyst comple-
mentation using other animals, such as pigs. Towards this goal,
the same group and their colleagues showed that this strategy
can be carried out using pancreatogenesis-disabled pigs, in
which Hes1 gene was overexpressed under the guide of the Pdx1
promoter33. Whole pig pancreas was generated by injecting the
blastocyst cells of other pigs into Pdx1-Hes1 transgenic pigs.
However, the generation of human pancreas using hESCs/
iPSCs and other animals by blastocyst complementation might
raise ethical concerns that the injected hESCs/iPSCs contribute
to other undesired organs in the generated chimeric animals,
such as the brain or reproductive organs. In an attempt to miti-
gate this concern, ESCs/iPSCs induced to commit into the tar-
geted organ lineage were used to prevent differentiation into
untargeted cell types in chimeric animals. It was reported that
the overexpression of a mesendoderm marker, Mixl1, induced
mouse ESCs to differentiate into endoderm, but not mesoderm,
in vitro. Based on this ﬁnding, the Nakauchi group used mouse
ESCs overexpressing the Mixl1 gene for blastocyst complemen-
tation and succeeded in restricting the localization of mouse
ESC derivatives into endodermal organs, such as the intestine34.
Additionally, a previous study reported that the more develop-
mentally advanced cell types than ESCs undergo apoptosis and
fail to contribute to chimera when injected into pre-implanta-
tion stage blastocysts35. The Nakauchi group, however, have
since succeeded in having these cells to contribute to chimera
by blastocyst complementation36. They injected mouse ESC-
derived Sox17+ endoderm progenitor cells overexpressing the
anti-apoptotic gene BCL2 into blastocysts. This approach
caused endoderm cells to integrate into the gut tissues of chi-
meric mice. Although there are still hurdles to overcome before
generating human pancreas in animal bodies, including ethical
issues, blastocyst complementation is an appealing strategy to
generate functional pancreas tissues from ESCs/iPSCs.
TRANSPLANTATION METHODS
In parallel with the generation of pancreas tissues from pluripo-
tent stem cells, the clinical application of induced pancreatic
cells has been explored. In general, transplantation strategies are
classiﬁed into two: (i) a method in which induced pancreas tis-
sues are directly implanted into the patient body; and (ii)
another in which a device that contains pancreatic tissues is
implanted (Figure 3). In the ﬁrst method, pretreatment to
induce angiogenesis in the implantation sites is used to pro-
mote the engraftment and long-term survival of the implanted
cells. One recent study reported that an embedded nylon cathe-
ter into the subcutaneous tissues of host mice for 1 month
before cell implantation generated vascularized space37. Here,
the embedded biomaterial induces the formation of vascular
networks in the implantation site, and pancreatic cells are
implanted after inﬂammatory reactions diminish, which makes
a less intolerant environment for the implanted cells.
In contrast, Szot et al.38 reported that the blockage of T-cell
costimulatory pathways by the administration of CTLA4Ig,
which suppresses T-cell activation, and an anti-CD154 antibody
prevented the rejection of xenogeneic implantation of hESC-
derived pancreatic endoderm cells into non-diabetic
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immunocompetent mice for >90 days. In that report, the implan-
tation of xenogeneic pancreatic endoderm cells differentiated
from hESCs into subcutaneous tissues of host diabetes mouse
models exerted therapeutic effects on diabetes without rejection.
In the second category of transplantation methods, pancreatic
cells are encapsulated by a bioengineered device that includes
semipermeable membranes. Oxygen and nutrients can pass to
promote cell survival, differentiation and maturation, whereas
immune molecules or cells cannot (Figure 3). It was reported
that hESC-derived pancreatic cells encapsulated by these
semipermeable membrane devices could further differentiate
into pancreatic b-cells even after implantation into host mice39.
In addition, because of vasculogenesis around the devices, the
differentiated b-cells can secrete insulin in response to changes
in glucose concentrations. Another report found that semiper-
meable membrane devices protected the rat islet grafts from
immune systems of wild-type host mice for at least 180 days
after transplantation40. A recent study reported the implanta-
tion of hESC-derived b-like cells encapsulated with an alginate
derivative, triazole-thiomorpholine dioxide alginate. This device
mitigated foreign body responses and implant ﬁbrosis, and
induced glycemic correction without immunosuppression for
>170 days in immunocompetent mice41.
These device-based implantation methods are expected to
reduce or eliminate the need for immunosuppressive agents. Fur-
thermore, these methods potentially have the advantage of remov-
ing the implanted cells with the device from the patient’s body
when adverse events, such as tumorigenesis or dysfunction, occur.
In 2014, ViaCyte Inc. started clinical trials for the treatment
of type 1 diabetes patients using a semipermeable membrane
capsule device that carried pancreatic progenitor cells differenti-
ated from hESCs. This trial has attracted attention worldwide,
as it represents an initial and important step for the develop-
ment of new stem cell therapies for diabetes.
DISEASE MODELING AND DRUG DISCOVERY
iPSC technology enables the creation of novel in vitro disease
models. Because iPSCs harbor the genetic information of
patients from which they are generated, the disease-affected cell
types differentiated from patient-derived iPSCs might reproduce
disease phenotypes in vitro. These approaches are especially
advantageous when reliable animal models are unavailable.
Diabetes patients











































Figure 3 | Device-based methods for implanting human embryonic stem cells and induced pluripotent stem cells (hESCs/iPSCs)-derived pancreatic
cells. hESC/iPSC-derived pancreatic cells encapsulated with immunoprotective devices are implanted into the bodies of diabetes animal models or
diabetes patients. Oxygen, nutrients, insulin and glucose can pass through the porous membrane of the device to promote the survival,
differentiation, maturation and glucose-responsive insulin secretion of encapsulated pancreatic cells. In contrast, immune cells or molecules, such as
antibodies and complements, cannot pass, which prevents immune rejection or autoimmune responses against the cells.
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Table 1 | Summary of reports on iPSCs derived from patients with diabetes-related disorders (as of February 2017)
Type of diabetes Mutation Findings References
Nondiabetic
mutation carrier
PDX1(C18R) Derivation of iPSCs from patients’ somatic cells 69
Nondiabetic
mutation carrier
PDX1(P33T) Derivation of iPSCs from patients’ somatic cells 68
Diabetic foot ulcer NA Derivation of iPSCs from patients’ somatic cells 67
T1D NA Efficient differentiation of patient-derived iPSCs into
glucose-responsive insulin-producing cells
66
T1D NA Differentiation of patient-derived iPSCs into b cells
in vitro
65





Exon 14 (nonsense; A897X), Exon 1
(missense; A2G), Exon 3 (missense;
L233P), Exon 2 (nonsense; E124X)
Patient-derived iPSCs showed mitochondrial
dysfunction with reduced mitochondrial size,
oxidative activity, and energy production
63
MODY5 HNF1B (S148L) Pancreatic progenitors from patient-derived iPSCs show






BSCL2/SEIPIN (E189X and R275X) Adipogenic differentiation of patient-derived iPSCs
exhibited reduction of lipid droplet formation
61
T1D NA Differentiation of patient-derived iPSCs into early







NA Analyses using patient-derived iPSCs revealed that
miR200-regulated DNA damage checkpoint pathway
protects against complications in T1D
59
MODY5 HNF1B (R177X) Patient-derived iPSCs showed mutant transcripts
destroyed by nonsense-mediated mRNA decay
58
MODY3 HNF1A Differentiation of patient-derived iPSCs into insulin-
expressing cells
57
T1D NA Differentiation of patient-derived iPSCs into functional





NA Creation of diabetic cardiomyopathy models from





NA Patient-derived iPSCs showed altered gene expression
and reduced proliferation
54
T1D NA Patient-derived iPSCs generated with synthetic mRNAs
encoding OCT4, SOX2, KLF4, c-MYC, and LIN28
upregulates pancreas-specific microRNAs
53
Wolfram syndrome WFS1 Pancreatic b-like cells from patient-derived iPSCs
showed increased ER stress led to insulin secretion
failure
52
MODY2 GCK GCK mutant b cells required higher glucose levels to
stimulate insulin secretion
51
MODY1, 2, 3, 5 and 8 MODY1: HNF4A, MODY2: GCK,
MODY3: HNF1A, MODY5: HNF1B,
MODY8: CEL
Derivation of iPSCs from patients’ somatic cells 50
T1D NA Multiple iPSC lines from individual patients showed
intrapatient variations in differentiation propensity to
insulin-producing cells
49
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Substantial efforts have already been made to analyze disease
mechanisms and develop novel therapeutic drugs using iPSC
disease models42.
As summarized in Table 1, multiple reports describe the gen-
eration of iPSCs from patients with diabetes-related disorders,
including types 1 and 2 diabetes mellitus; maturity-onset
Table 1 (Continued)
Type of diabetes Mutation Findings References
T2D NA Marked hyperglycemia disrupted anesthetic
preconditioning-mediated protection in
cadiomyocytes from patient-derived iPSCs
48
T1D and T2D NA Derivation of transgene-free iPSCs from patients using
Sendai viral vectors
47




mtDNA (A3243G) Patient-derived iPSCs showed a bimodal degree of
mutation heteroplasmy; mutation-free and -rich iPSC clones
45
T2D NA Derivation of iPSCs from elderly T2D patients and
differentiation into insulin-producing islet-like progeny
44
T1D NA Differentiation of patient-derived iPSCs into insulin-
producing cells in vitro
11
T1D NA Derivation of iPSCs from patients’ somatic cells 43


















Figure 4 | Disease modeling using patient-derived induced pluripotent stem cells (iPSCs). (a) In vitro type 1 diabetes disease models using the
differentiation of patient-derived iPSCs into pancreatic b- and immune cells. (b) iPSCs derived from a type 1 diabetes patient and (c) insulin-
secreting cells differentiated from the iPSCs. Scale bars, 300 μm in (b) and 100 μm in (c). Figures (b) and (c) were provided by Drs Yoshiya
Hosokawa, Akihisa Imagawa and Iichiro Shimomura, Department of Metabolic Medicine, Osaka University Graduate School of Medicine.
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diabetes of the young types 1, 2, 3, 5 and 8, in which a single
gene mutation causes diabetes; and mitochondria diabetes11,43–69.
A report analyzing maturity-onset diabetes of the young type 2
showed that iPSC models can reproduce the disease phenotype
caused by mutations in a glucokinase gene that cause a decrease
in insulin secretion by glucose stimulation51. However, although
many of these reports have shown the generation of patient-
derived iPSCs and their in vitro differentiation into b-like insu-
lin-producing cells, they have not reported the recapitulation of
the disease phenotypes. The reason is that the b-like cells gener-
ated from patient-derived iPSCs are insufﬁcient to recapitulate
the phenotypes of diseases that are caused by a complex cellular
environment including multiple cell types, such as immune cells.
As described above, cells that functionally resemble adult b-cells
can now be produced from human pluripotent stem cells
in vitro. Combining multiple cell types in vitro with iPSC-
derived b-like cells could create novel diabetes disease models
that better elucidate the disease mechanisms and facilitate the
discovery of novel therapeutics drugs (Figure 4).
CONCLUSION
Basic research on cell therapy strategies for diabetes using stem
cells has advanced considerably in the past decade. The genera-
tion of functional pancreatic tissues from human pluripotent
stem cells has become possible, and these cells could replace
the donor islets used in islet transplantation. In the next decade,
it is expected that many experimental diabetes treatments will
be conﬁrmed for therapeutic efﬁcacy and safety.
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